TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14751472

Group type: EXPERIMENTAL
Intervention: Digital intraoral manipulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Without digital intraoral manipulation
Number of subjects: 100
Study: 15104377

Group type: EXPERIMENTAL
Intervention: Short-term acupoint TENS
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Long-term acupoint TENS (2-month treatment)
Number of subjects: 104

Group type: COMPARATOR
Intervention: IBS-D patients
Number of subjects: 104

Group type: COMPARATOR
Intervention: IBS-C and FC patients
Number of subjects: 104
Study: 10396146

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (other chronic inflammatory diseases)
Number of subjects: 14
Study: 7742428

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg to 400 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 24
Study: 2167795

Group type: EXPERIMENTAL
Intervention: Dye dilution method (Indocyanine Green dye infusion into the femoral artery)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Strain-gauge plethysmography
Number of subjects: 8

Group type: COMPARATOR
Intervention: Catheterization and sham punctures
Number of subjects: 8

Group type: COMPARATOR
Intervention: Blood gas and substrate concentration measurements
Number of subjects: 8
Study: 7023742

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30716598

Group type: EXPERIMENTAL
Intervention: PIPE program plus routine care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 62
Study: 26714009

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Oxybutynin 15 mg
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 27074057

Group type: EXPERIMENTAL
Intervention: Violent-sexist video game
Number of subjects: 154

Group type: COMPARATOR
Intervention: Violent-only video game
Number of subjects: 154

Group type: COMPARATOR
Intervention: Non-violent game
Number of subjects: 154
Study: 25178590

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2mg/4mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (4mL normal saline)
Number of subjects: 66
Study: 21716130

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg QD for 7 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg QD for 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study: 19901104

Group type: EXPERIMENTAL
Intervention: RT followed by adjuvant PCV chemotherapy
Number of subjects: 368

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 368
Study: 17869978

Group type: EXPERIMENTAL
Intervention: Pressure assist-control ventilation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Volume assist-control ventilation (VACV)
Number of subjects: 12
Study: 14692007

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive‐expressive dynamic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual drug counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group drug counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 0
Study: 11985485

Group type: COMPARATOR
Intervention: Intravenous infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple infusions of infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple infusions of infliximab plus methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab plus methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 0
Study: 9813532

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg kg-1
Number of subjects: 245
Study: 8733263

Group type: EXPERIMENTAL
Intervention: Non-invasive intermittent mechanical ventilation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Simulated ventilation (control)
Number of subjects: 21
Study: 31597621

Group type: EXPERIMENTAL
Intervention: Resistance exercise training sessions three times per week with daily oral cholecalciferol supplementation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard medical care (Control)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Resistance exercise training and cholecalciferol supplementation
Number of subjects: 39
Study: 31359435

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Individual/Group Supportive Therapy (IGST)
Number of subjects: 173
Study: 28076331

Group type: EXPERIMENTAL
Intervention: Selenium (300 µg per day in the form of selenized yeast)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24925504

Group type: EXPERIMENTAL
Intervention: Light Protected (LP) group
Number of subjects: 590

Group type: COMPARATOR
Intervention: Light Exposed (LE) group
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: All-in-one PN
Number of subjects: 590

Group type: COMPARATOR
Intervention: Lipids separately
Number of subjects: 590
Study: 24298766

Group type: EXPERIMENTAL
Intervention: Acupuncture (penetrating needling at head acupoints)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Medication (loratadine tablet and azelastine hydrochloride nasal spray)
Number of subjects: 81
Study: 20716757

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 436

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 436

Group type: COMPARATOR
Intervention: No tirofiban
Number of subjects: 436
Study: 18165210

Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.1%
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine ophthalmic solution 0.4%
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bromfenac 0.09%
Number of subjects: 29
Study: 15752391

Group type: EXPERIMENTAL
Intervention: Immediate cessation of sevoflurane
Number of subjects: 85

Group type: COMPARATOR
Intervention: Gradual decrease of sevoflurane (0.1% min(-1))
Number of subjects: 85
Study: 12095313

Group type: EXPERIMENTAL
Intervention: VEGF-adenovirus (VEGF-Ad) - 2x10(10) plaque-forming units (pfu)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: VEGF-plasmid/liposome (VEGF-P/L) - 2000 microg of VEGF plasmid, 2000 microl of DOTMA:DOPE
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ringer's lactate (control)
Number of subjects: 54
Study: 10376228

Group type: EXPERIMENTAL
Intervention: Pre-operative education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pre-operative education)
Number of subjects: 0
Study: 7484890

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 800

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 800
Study: 2272044

Group type: EXPERIMENTAL
Intervention: FEC every 3 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: LMF (leukeran, methotrexate, 5‐fluorouracil) every 6 weeks
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: FEC (5‐fluorouracil, 4‐epirubicin, cyclophosphamide)
Number of subjects: 99
Study: 7032640

Group type: EXPERIMENTAL
Intervention: Adriamycin (50 mg in 50 ml of saline for 30 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study: 31855162

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 861
Study: 28028192

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 9270

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 9270
Study: 25833777

Group type: EXPERIMENTAL
Intervention: HGI-LF breakfast (high glycemic index, low fiber)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HGI-LF breakfast
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LGI-LF breakfast
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LGI-HF and LGI-LF breakfasts
Number of subjects: 14
Study: 23512156

Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation (RMN) for circumferential pulmonary vein ablation (PVA)
Number of subjects: 138
Study: 21800045

Group type: EXPERIMENTAL
Intervention: Fact sheet listing two causes of colon cancer (polyps and cause unknown) and six ways to help prevent colon cancer (lifestyle, diet, weight, smoking, alcohol, and screening)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fact sheet intervention
Number of subjects: 66
Study: 19682173

Group type: EXPERIMENTAL
Intervention: Probiotic milk drink (once a day for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no product to drink)
Number of subjects: 50
Study: 17966758

Group type: EXPERIMENTAL
Intervention: Chlorpropamide 250 mg tablet (test formulation)
Number of subjects: 36
Study: 16321616

Group type: COMPARATOR
Intervention: 20 mg lisinopril
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20 mg olmesartan medoxomil
Number of subjects: 30

Group type: COMPARATOR
Intervention: 40 mg olmesartan medoxomil
Number of subjects: 30

Group type: COMPARATOR
Intervention: 80 mg olmesartan medoxomil
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20 mg lisinopril plus 20 mg olmesartan medoxomil
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20 mg lisinopril plus 40 mg olmesartan medoxomil
Number of subjects: 30
Study: 11912111

Group type: EXPERIMENTAL
Intervention: Finger tracking training (18-20 sessions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no treatment during control period)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Finger tracking training
Number of subjects: 10
Study: 9797755

Group type: EXPERIMENTAL
Intervention: Inhaled LPS (60 micrograms)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 26
Study: 7648773

Group type: EXPERIMENTAL
Intervention: Velnacrine maleate 150 mg/day
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Velnacrine maleate 225 mg/day
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 2705425

Group type: EXPERIMENTAL
Intervention: In-person interviews
Number of subjects: 342

Group type: COMPARATOR
Intervention: Mail approaches
Number of subjects: 342

Group type: COMPARATOR
Intervention: Mail methodologies
Number of subjects: 342
Study: 792477

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 30843501

Group type: EXPERIMENTAL
Intervention: 600 IU daily vitamin D3 supplementation
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: 1000 IU daily vitamin D3 supplementation
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: 2000 IU daily vitamin D3 supplementation
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1008
Study: 29356445

Group type: EXPERIMENTAL
Intervention: Repeated exposure to weather-related stressors (30 min of a 3°C decrease in temperature, simulated rain, or 2 hr of food removal, 4 times daily for 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the absence of the experimental stressors)
Number of subjects: 0
Study: 25809925

Group type: EXPERIMENTAL
Intervention: Pilates exercise program (G1)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: PFME combined with anal electrical stimulation (G2)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (G3)
Number of subjects: 85
Study: 25128510

Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 78
Study: 21626613

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic group psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic group psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both short-term and long-term psychodynamic group psychotherapy
Number of subjects: 0
Study: 19671655

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months for 36 months
Number of subjects: 7868

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7868
Study: 17184430

Group type: EXPERIMENTAL
Intervention: Upper-body warming (UBW)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lower-body warming (LBW)
Number of subjects: 73
Study: 16280694

Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus optimized background regimen (OB)
Number of subjects: 995

Group type: COMPARATOR
Intervention: Control group (optimized background regimen only)
Number of subjects: 995
Study: 12160199

Group type: EXPERIMENTAL
Intervention: Tamoxifen (continued)
Number of subjects: 23
Study: 10437288

Group type: EXPERIMENTAL
Intervention: Bishop score > or = 6
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cervical length < or = 26 mm
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Positive FNf assay
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Fibronectin assay
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Bishop score
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cervical length
Number of subjects: 128
Study: 8846489

Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg (M25)
Number of subjects: 3673

Group type: EXPERIMENTAL
Intervention: Mefloquine 15 mg/kg (M15)
Number of subjects: 3673

Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg (M25) split dose
Number of subjects: 3673

Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg (M25) with artesunate on the second day
Number of subjects: 3673
Study: 2210983

Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injections combined with internal urethrotomy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injections
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Internal urethrotomy
Number of subjects: 38
Study: 434434

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (4 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% (4 ml)
Number of subjects: 0
Study: 31927404

Group type: EXPERIMENTAL
Intervention: Infant Behavior Program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard pediatric primary care
Number of subjects: 58
Study: 30144462

Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation (10 min at 1.5 mA) over the left DLPFC at Fp3
Number of subjects: 144

Group type: COMPARATOR
Intervention: Active control (different tDCS targeted brain area)
Number of subjects: 144
Study: 26834462

Group type: EXPERIMENTAL
Intervention: Cariprazine (3, 6, or 9 mg/day)
Number of subjects: 38
Study: 24842200

Group type: EXPERIMENTAL
Intervention: HES-Group (Colloid Prime)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Crystalloid Group (Ringer's Lactate)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HES-Group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Crystalloid Group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 40
Study: 22882724

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg once-daily for 12 weeks
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 20661103

Group type: EXPERIMENTAL
Intervention: 3 + 1 regimen (PCV7 at 2, 4, 6, and 12 months)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: 2 + 1 regimen (PCV7 at 4, 6, and 12 months)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: 3 + 0 regimen (PCV7 at 2, 4, and 6 months)
Number of subjects: 543
Study: 18365859

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) for 12 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hormone therapy (HT) for 24 months
Number of subjects: 45
Study: 15997446

Group type: EXPERIMENTAL
Intervention: Laparoscopic rectal surgery
Number of subjects: 347

Group type: COMPARATOR
Intervention: Open rectal surgery
Number of subjects: 347

Group type: COMPARATOR
Intervention: Female sexual function
Number of subjects: 347
Study: 15131517

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 20
Study: 10573241

Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 53
Study: 8920706

Group type: EXPERIMENTAL
Intervention: RRV vaccine (10^4 p.f.u.)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Serotype G2 vaccine
Number of subjects: 800

Group type: COMPARATOR
Intervention: Serotype G1 or G2 vaccines
Number of subjects: 800
Study: 1864291

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (enoxacin, ofloxacin, pefloxacin, ciprofloxacin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New quinolones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinolones with or without erythromycin and rifampin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinolones
Number of subjects: 0
Study: 6836636

Group type: EXPERIMENTAL
Intervention: Preoperative radiation (18 to 21 Gy for one week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nephrectomy and postoperative radiation (no preoperative radiation)
Number of subjects: 60
Study: 31053082

Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index (HPI) software guidance
Number of subjects: 213

Group type: COMPARATOR
Intervention: Blinded monitoring
Number of subjects: 213

Group type: COMPARATOR
Intervention: Unblinded monitoring
Number of subjects: 213
Study: 29870325

Group type: EXPERIMENTAL
Intervention: Optimal Medicine Treatment (OMT) + Education Program and Active Outpatient Monitoring (OMT + A)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Optimal Medicine Treatment (OMT)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Optimal Medicine Treatment (OMT) + Additional Exposure (DV)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Optimal Medicine Treatment (OMT) + DV
Number of subjects: 237
Study: 27919453

Group type: EXPERIMENTAL
Intervention: Tartary buckwheat (TB) intervention group (daily replacement of a portion of staple food with TB food)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Tartary buckwheat (TB) intervention group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control diet group (DC group; systematic diet plans and intensive nutritional education)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Tartary buckwheat (TB) intervention group (greater than 110 g/d)
Number of subjects: 165
Study: 24213956

Group type: EXPERIMENTAL
Intervention: MT + MG
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MT
Number of subjects: 43

Group type: COMPARATOR
Intervention: CT
Number of subjects: 43
Study: 22316357

Group type: EXPERIMENTAL
Intervention: 25% discount on fruits and vegetables (experimental condition)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Regular prices (control condition)
Number of subjects: 115
Study: 19577442

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 0
Study: 17984375

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich dark chocolate (40 g, 70% cocoa)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich dark chocolate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cocoa-free control chocolate
Number of subjects: 22
Study: 15964131

Group type: EXPERIMENTAL
Intervention: Hysterocolposacropexy (HSP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hysterectomy followed by sacropexy (CSP)
Number of subjects: 72
Study: 12032406

Group type: EXPERIMENTAL
Intervention: Intensive altitude training (3100 m for 6 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no regular physical activity)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Altitude training effect on nitrite/nitrate levels
Number of subjects: 9
Study: 9719328

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Carotid angioplasty (CA)
Number of subjects: 23
Study: 7695416

Group type: EXPERIMENTAL
Intervention: Retransfusion of suctioned blood (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retainment of suctioned blood (n = 21)
Number of subjects: 40
Study: 2973471

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic hormone (ANH) infusion (0.75 pmol/kg.min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31112230

Group type: EXPERIMENTAL
Intervention: Serum Adiponectin (APN) levels
Number of subjects: 3361
Study: 30307347

Group type: EXPERIMENTAL
Intervention: Scenario-based training (Arm 2)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Combination of scenario-based and conventional training (Arm 3)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional asthma training (Arm 1)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 204
Study: 28162145

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy using a mobile application (CBT‐I‐MA)
Number of subjects: 19
Study: 25752995

Group type: EXPERIMENTAL
Intervention: Community engagement strategies including convening a Community Engagement Studio, redesigning recruitment advertisement, simplifying language, providing transportation
Number of subjects: 0
Study: 23319696

Group type: EXPERIMENTAL
Intervention: FLAG plus DNX
Number of subjects: 394

Group type: COMPARATOR
Intervention: FLAG
Number of subjects: 394
Study: 16488056

Group type: EXPERIMENTAL
Intervention: Same Snack condition (crumb cake)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Variety condition (different sweet and salty snacks)
Number of subjects: 21
Study: 14504877

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E(2)) 0.05 mg/day for the first 14 days, followed by 0.05 mg/day E(2) plus 0.25 mg/day norethisterone acetate (NETA) for another 14 days, for a total of 48 weeks.
Number of subjects: 748

Group type: COMPARATOR
Intervention: Control group (non-symptomatic women)
Number of subjects: 748